Clinical Trial Update: Randomized Safety Study of CVT-301 Compared to an Observational Control Group [Phase 3]

View source ↗

Summary

A completed Phase 3 randomized safety study comparing CVT-301 to an observational control in idiopathic Parkinson's disease with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Parkinson Disease

Drugs mentioned

• CVT-301 (levodopa inhalation powder)

Snippet

Sponsor: Acorda Therapeutics | Conditions: Idiopathic Parkinson's Disease | Phase 3 | Status: COMPLETED | Results posted: 2018-07-10